Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danai Dima

Showing results (61-70 of 161) with videos related to

Pageof 17
Sort By:
Brain, Behavior, and Immunity|November 7, 2020
Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depressionFederico E Turkheimer, Noha Althubaity, Julia Schubert, et al.
Hematological Oncology|June 13, 2023
A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapiesRahul Mishra, Danai Dima, Sumukh A Kumar, et al.
Molecular Psychiatry|March 6, 2026
Transcriptome-informed brain cartography of polygenic risk and association with brain structure in major psychiatric disordersAlessio Giacomel, Timothy R Powell, Rodrigo R R Duarte, et al.
Journal of Clinical Medicine|April 13, 2024
Role of Palliative Care in the Supportive Management of AL Amyloidosis-A ReviewMuhammad Hamza Habib, Yun Kyoung Ryu Tiger, Danai Dima, et al.
British Journal of Haematology|April 23, 2026
Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR dataUtkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple MyelomaDanai Dima, Mark Orland, Fauzia Ullah, et al.
Blood Cancer Journal|December 20, 2024
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance studyMajid Jaberi-Douraki, Xuan Xu, Danai Dima, et al.
Journal of Medical Economics|March 18, 2026
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settingsMurali Janakiram, Lin Fan, Sabyasachi Ghosh, et al.
Cancers|April 13, 2023
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical PracticeDanai Dima, Fauzia Ullah, Sandra Mazzoni, et al.
Hematological Oncology|April 13, 2025
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic CenterDanai Dima, Utkarsh Goel, Fauzia Ullah, et al.
Pageof 17

Showing results (61-70 of 161) with videos related to

Sort By:
Pageof 17
Brain, Behavior, and Immunity|November 7, 2020
Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depressionFederico E Turkheimer, Noha Althubaity, Julia Schubert, et al.
Hematological Oncology|June 13, 2023
A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapiesRahul Mishra, Danai Dima, Sumukh A Kumar, et al.
Molecular Psychiatry|March 6, 2026
Transcriptome-informed brain cartography of polygenic risk and association with brain structure in major psychiatric disordersAlessio Giacomel, Timothy R Powell, Rodrigo R R Duarte, et al.
Journal of Clinical Medicine|April 13, 2024
Role of Palliative Care in the Supportive Management of AL Amyloidosis-A ReviewMuhammad Hamza Habib, Yun Kyoung Ryu Tiger, Danai Dima, et al.
British Journal of Haematology|April 23, 2026
Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR dataUtkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 9, 2023
Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple MyelomaDanai Dima, Mark Orland, Fauzia Ullah, et al.
Blood Cancer Journal|December 20, 2024
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance studyMajid Jaberi-Douraki, Xuan Xu, Danai Dima, et al.
Journal of Medical Economics|March 18, 2026
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settingsMurali Janakiram, Lin Fan, Sabyasachi Ghosh, et al.
Cancers|April 13, 2023
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical PracticeDanai Dima, Fauzia Ullah, Sandra Mazzoni, et al.
Hematological Oncology|April 13, 2025
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic CenterDanai Dima, Utkarsh Goel, Fauzia Ullah, et al.
Pageof 17